Our results suggest that empagliflozin treatment downregulates the interaction of the de novo pathway and the catabolic pathway of sphingolipid metabolism in the diabetes, whereas in Ang II-dependent hypertension, it only downregulates the sphingolipid catabolic pathway. This evidence concerns the gene AGT and diabetes mellitus.